Background and Aims: The rate of hospital readmission after discharge has been studied extensively in chronic conditions such as hepatic cirrhosis,
I
nflammatory bowel disease (IBD) is a chronic idiopathic inflammatory disorder of the digestive tract, comprised primarily by ulcerative colitis (UC) and Crohn's disease (CD). The natural history of IBD is characterized by frequent exacerbations, some of which mandate hospitalization. The economic impact of IBD is considerable, with a rising incidence coupled with an estimated prevalence of approximately 1.4 million people in United States. 1 This ever-expanding population and the related increasing rates of hospitalization are leading to increased health care resource utilization: between 1990 and 2003, the hospitalization rates for patients with CD were 9.3 to 17.1 per 100,000 people and were 8.2 to 12.4 per 100,000 people for UC. 2 In another study by Nguyen et al, 3 between 1998 and 2004, the hospitalization rate for CD was 18 per 100,000 people and UC was 10.8 per 100,000 people. In a study by Ananthakrishnan et al, 4 the rising hospitalization rates were attributed to a significant rise in low to intermediate severity hospitalizations. Hospitalizations account for significant direct costs for both patients with UC and CD (37.6% and 31.4%, respectively, of total costs per patient per year). 5 There were a total of 97,865 hospitalizations for IBD in the year 2013 based on national inpatient sample. 6 With the recent passage of the Affordable Care Act (ACA), 7 there has been a significant interest in determining and reducing costs associated with medical care. One particular area of interest has been in hospital readmissions after disposition.
Although previous studies have suggested that moderate to severe disease activity, psychological comorbidity, number of medications, and outpatient visits may predict hospitalization, there are limited data regarding what factors predict subsequent readmission. 8, 9 A recent study by Tinsley et al 10 showed that extensive colitis, low albumin at admission, and getting admitted to a housestaff service were independent risk factors for early readmission.
In this study, we aimed to determine the causes of readmissions and factors predictive of readmissions in patients with IBD. We hypothesized that patients with severe flares needing intensive care unit (ICU) stays or inpatient biologics were more likely to be readmitted frequently.
METHODS

Study Design
We performed a retrospective cohort study of individuals with IBD within the University of Pennsylvania Health System. The data warehouse for the University of Pennsylvania comprises 3 large academic hospitals (Hospital of the University of Pennsylvania, Presbyterian Medical Center, and Pennsylvania Hospital). This data store was queried to identify patients with IBD within Philadelphia, Pennsylvania, for inclusion. The study was approved by the University of Pennsylvania's institutional review board.
Inclusion and Exclusion Criteria
All patients older than 18 years with a discharge diagnosis of CD or UC who were unexpectedly admitted to Hospital of the University of Pennsylvania, Presbyterian Medical Center, or Pennsylvania Hospital from January 2007 to December 2010 were included. Those who died during this admission were excluded.
Outcome Definition
The primary outcome of interest was hospital readmission at a University of Pennsylvania Health System hospital. Readmission was defined as an unplanned hospital admission because of any cause occurring within 1 month, 3 months, or 1 year from the index admission.
Exposures of Interest
To identify factors predictive of readmissions, we assessed social, demographic, and clinical features at the time of the index admission. The following data were evaluated: demographics (age, sex, and race), type of insurance (public versus private versus no insurance), source of admission (emergency department, transfer from another institution, and direct admit), admitting service (gastroenterology versus medicine versus surgery), type of IBD (UC versus CD), duration of disease, new diagnosis of IBD at index admission, history of surgery before index admission, unplanned surgery during index admission, lower gastrointestinal endoscopy during index admission (either flexible sigmoidoscopy or colonoscopy), medications received during index admission and at discharge (antibiotics, steroids, mesalamine, immune modulators, and biologics), use of total parenteral nutrition (TPN) during index admission, ICU stay, transfusions during index admission, and a history of documented psychiatric illness. Causes of readmissions were defined by International Classification of Diseases, Ninth Revision, discharge diagnosis codes.
Statistical Analyses
Descriptive statistics were performed comparing baseline characteristics at the time of initial assessment among those with readmission and without using chi-square tests, t tests, Wilcoxon rank-sum tests, and Fisher's exact tests where appropriate. Three multivariate logistic regression models were built to describe predictors of IBD readmissions at 1-month, 3-month, and 1-year periods. Models were constructed with the backward stepwise method. Variables with univariate significance levels of less than 0.1 were included in multivariate models for each outcome. Only variables with P values less than 0.15 were retained in the final models. 11 Statistical analyses used STATA S/E 13.1 (College Station, Tx).
RESULTS
A total of 439 patients had an index admission with primary discharge diagnosis codes of either UC (n ¼ 144, 33%) or CD (n ¼ 295, 67%) during the study period. These patients accounted for a total of 785 admissions to the health system during the study period. The demographics and baseline clinical characteristics of the study cohort are reported in Table 1 .
Early Readmissions
A total of 62 (14.1%) patients were readmitted at least once within 1 month of discharge with 10% of the study cohort being admitted more than once ( Table 1 ). The median length of stay at the index admission for patients readmitted again within 1 month of the initial admission was 7 days (interquartile range [IQR] ¼ 5) versus 5 days (IQR ¼ 5) for those not readmitted (P ¼ 0.001). Among the 62 patients readmitted at least once in 1 month, 22 (35.5%) were readmitted within 1 week. Thus, the 1-week readmission rate was 5%. Six patients were readmitted more than once within 1 month. The most common cause of readmission was IBD (43.5%), followed by infection (17.4%), abdominal pain (5.8%), and gastrointestinal bleeds (2.9%). The most prevalent infections were as follows: pneumonia (4.6%), cellulitis (4.6%), and postoperative infections (3.2%). There were no cases of C. difficile or Methicillin-resistant Staphylococcus aureus (MRSA). The most common reasons for readmission are listed in Table 2 .
In the univariate analysis, 6 factors were associated with a risk of readmission at 1 month (P , 0.1): receipt of steroids at admission (P ¼ 0.09), TPN use at index admission (P ¼ 0.002), blood transfusion at index admission (P ¼ 0.08), ICU stay at index admission (P ¼ 0.0001), length of stay at index admission (P ¼ 0.001), and surgery at index admission (P ¼ 0.02) ( Table 1) . 
38 (15) 38 (13) 38 (15) 38 (15) 38 (15) 38 ( Table 3 ). Receipt of steroids at index admission trended toward a protective effect against readmission but was not statistically significant (OR, 0.52; 95% CI, 0.23-1.15; P ¼ 0.11) ( Table 3 ).
Readmissions at 3 Months
A total of 104 (23.7%) patients were readmitted at least once within 3 months of discharge. These patients accounted for a total of 133 readmissions within 3 months, with 20% of the cohort being admitted more than once ( Table 1 ). The median length of stay during the index admission for readmitted patients at 3 months was 7 days (IQR ¼ 5) versus 5 days (IQR ¼ 5) for those without readmission (P ¼ 0.003). The most common cause of readmission was IBD (48.9%), followed by infection (16.5%), abdominal pain (6.0%), and postoperative complications (5.3%). The most prevalent infections are listed in Table 2 .
In the univariate analysis, 7 factors were associated with an increased risk of readmission at 3 months (P , 0.1): type of IBD (P ¼ 0.06), whether or not they received mesalamine at index admission (P ¼ 0.05), whether they were discharged on biologics (P ¼ 0.04), TPN use at index admission (P ¼ 0.05), blood transfusion at index admission (P ¼ 0.06), length of stay at index admission (P ¼ 0.003), and ICU stay at index admission (P , 0.001) ( Table 1) . However, the statistical significance of mesalamine did not hold when UC and CD cases were analyzed separately; it only remained significant for patients with CD. In the multivariate analysis, hospital readmission at 3 months was statistically significantly independently predicted by mesalamine use at admission (OR, 1.68; 95% CI, 1.06-2.69; P ¼ 0.029) and stay in the ICU during index admission (OR, 3.61; 95% CI, 1.38-9.46;
The association between receipt of TPN at index admission and hospital readmission trended toward a positive effect (OR, 1.66; 95% CI, 0.94-2.93; P ¼ 0.08) but was not statistically significant (Table 4) . Conversely, being discharged on biologics trended toward a protective effect, but was also not statistically significant (OR, 0.44; 95% CI, 0.19-1.02; P ¼ 0.054) ( Table 4 ).
Readmissions at 1 Year
A total of 172 (39.2%) patients were readmitted at least once within 1 year of discharge. These patients accounted for a total of 346 readmissions within 1 year, with 46% of the cohort being admitted more than once ( Table 1 ). The median length of stay during the index admission for readmitted patients was 6 days (IQR ¼ 5) versus 5 days (IQR ¼ 5) for those without readmissions (P ¼ 0.003). The most common cause of readmission was IBD (46.8%), followed by infection (15.6%), postoperative complications (6.4%), and abdominal pain (5.5%). The most common reasons for readmission are listed in Table 2 .
Univariate analysis yielded 11 variables that were associated with risk of readmission at 1 year (P , 0.1): sex (P ¼ 0.06), race (P ¼ 0.03), source of admission (P ¼ 0.03), insurance (0.005), surgery at index admission (P ¼ 0.08), mesalamine at index admission (P ¼ 0.04), narcotics at index admission (P ¼ 0.09), narcotics at discharge (P ¼ 0.05), receipt of TPN at index admission (P ¼ 0.02), length of stay at index admission (P ¼ 0.003), and an ICU stay at index admission (P ¼ 0.002). In the multivariate model, hospital readmission was statistically significantly associated with being male (OR, 1.58; 95% CI, 1.05-2.37; P ¼ 0.03), being black compared with whites (OR, 1.70; 95% CI, 1.04-2.77; P ¼ 0.04), being admitted by a transfer from an outside hospital compared with being admitted through emergency department (OR, 2.43; 95% CI, 1.06-5.62; P ¼ 0.04) and having to stay in the ICU during 
DISCUSSION
In the recent past, there has been a great emphasis on reducing hospital readmissions. A large number of studies have attempted to identify risk factors for readmissions in chronic diseases such as asthma, chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), and cirrhosis. [11] [12] [13] [14] [15] There are limited data regarding those modifiable factors that may be associated with an increased risk of subsequent readmission in patients with IBD. The aim of our study was to identify causes and independent risk factors for all cause unplanned hospital readmissions in patients with IBD. We hypothesized that admission to the ICU and receipt of inpatient biologics during the index admission would be the best predictors of patient readmission to the hospital during the subsequent year. ICU stay was a predictor for readmission at 1 month, 3 months and 1 year, wheraes biologics at discharge trended toward a nonsignificant protective effect at 1 year. Similar to other chronic diseases such as liver cirrhosis, COPD, congestive CHF, our results demonstrate that patients with IBD also have both high early and late readmission rates. [11] [12] [13] [14] [15] We showed that approximately 5% of patients with IBD are readmitted within 1 week of discharge, 14% are readmitted within 1 month, 23% are readmitted within 3 months, and 39% are readmitted within 1 year. Readmission rates in our study are similar to another single-center study from the United States, looking at readmissions in patients with IBD, which demonstrated an 18% readmission rate at 1 month but are much higher when compared with a recent population-based study from Canada that had a 2.3% 1-month readmission rate and a 7.7% at 1 year. 8, 9 One possible explanation for the very low readmission rates seen in the Canadian study is that they defined IBD readmissions as admissions where IBD was the principal diagnosis. 9 We included all unplanned readmissions due any cause after the index admission. In our study, the readmission rates were still higher (6.6% at 1 month, 10% at 3 months, and 20% at 1 year), even if we considered only readmissions with IBD as the principal discharge diagnosis. The high readmissions rate seen in our study coincides with recent reports of increasing hospitalizations among patients with IBD in the United States.
Our study is also one of the first to assess the underlying etiology of subsequent readmission among patients with IBD. Although IBD flares accounted for almost 50% of readmissions at all 3 time points, non-IBD-related causes also led to an equally large number of readmissions. Among non-IBD-related causes, infections played a major role and were responsible for almost 20% of readmissions at all 3 time points. These results are similar to another recent single-center study, where infections led to 27.6% of readmissions at 1 month. 8 Common infections causing readmissions were pneumonia, cellulitis, and postoperative infections. These results are not surprising, as patients with IBD are at an increased risk of infections because of both disease severity and the immunosuppressive medications they receive. 16 Recent studies have also shown that patients with IBD are at increased risk of Clostridium difficile and MRSA infections. 17, 18 However, our cohort had only 3 cases of C. difficile and no cases of MRSA infections. One possible explanation for no MRSA infections in our cohort could be extensive and strict MRSA precautions initiated in our health system to decrease MRSA infections.
Postoperative surgical complications (including postoperative infections) were another major contributor to hospital readmissions, especially at 3 months (7.5%) and 1 year (9.2%). In a prospective study on predictors of readmission in patients undergoing laparoscopic surgery, IBD was found to be an independent risk factor for readmissions. 19 In a study by Hazratzee et al, 8 pain played a major role in readmissions, leading to 49.5% of readmissions. In our study, abdominal pain contributed to ,10% of readmissions for all 3 time points.
This study is also one of the first to examine factors associated with an increased risk of readmission. We demonstrated that factors associated with increased severity of illness, such as ICU stay or TPN use, are significantly associated with an increased risk of readmission. These results are consistent with previous work demonstrating that ICU stay is associated with significant morbidity and mortality in patients with IBD. A recent study by Ha et al demonstrated that admission to an ICU was associated with a significant mortality rate of 18.9%, longer length of stay, and an increased risk of readmission in 30 days. This effect was most prominent in those with CD compared with those with UC (54.5% versus 15.6%). 20 Therefore, these patients may represent a window of opportunity to reduce readmissions as intensive discharge planning in these patients might prevent readmission.
Previous research has also indicated that surgical resections may reduce the risk of short-term rehospitalization. 9 Although our study found that patients who underwent unplanned surgery at the time of the index admission had an increased risk of readmission at 1 month on univariate analysis, this was not significant after adjusting for other covariates.
We were also able to assess the impact of a number of medications on subsequent rehospitalization. Interestingly, we found that patients treated with steroids at the time of index admission had a decreased risk of readmission at 1 month, although this effect did not reach statistical significance. This is likely multifactorial: steroids are known to have a relatively high success rate in inducing remission, while also often requiring extended tapers beyond 1 month. 21, 22 The fact that this effect was not observed at 3 months and 1 year supports this hypothesis. We also found that patients who were discharged on biologics were less likely to be readmitted at 3 months. This is probably related to the efficacy of biologics in inducing and maintaining remission in moderate to severe IBD flares. Interestingly, biologics did not prevent 1-year readmissions. Because we did not review the outpatient records of our study cohort, it is difficult to assess the reason for this. Possible reasons could be noncompliance, inability to tolerate biologics long term, and other factors such as loss of efficacy.
A single-center retrospective study of 229 patients evaluating the incidence and risk factors for early readmission in patients with UC noted a 30-day readmission rate of 11.7% and a 90-day readmission rate of 20.5%, which is similar to our study. In this study cohort, 47% were readmitted for colectomy after they failed medical therapy. Extensive colitis was noted to be a risk factor for 30-day readmission (OR ¼ 3.59; 95% CI, 1.41-9.13), whereas extensive colitis (OR ¼ 3.09, 95% CI, 1.33-7.08), albumin on admission (OR ¼ 0.56; 95% CI, 0.31-0.99), and being admitted to housestaff service predicted 90-day readmission (OR ¼ 2.87; 95% CI, 1.14-6.54). Results of this study similar to ours show that patients with more severe disease (extensive colitis, low albumin level) are more likely to be readmitted. 10 Similar to other studies on readmissions, we also found that having Medicare/Medicaid insurance was a risk factor for readmission. 23 In a study by Jencks et al, patients with Medicare had a readmission rate of 20% at 1 month and 56% at 1 year. 24 We also found that patients with no insurance were less likely to be readmitted than those with public insurance (Medicare, Medicaid). One possible explanation is that this patient population was lost to follow-up and obtained care elsewhere.
Hospital readmissions have been of increased focus in the recent times. Readmissions within 30 days account for around $17 billion unavoidable Medicare expenditures. 24, 25 To reduce readmissions ACA introduced the Hospital Readmissions Reduction Program (HRRP) in 2012. Under HRRP, hospitals with higher than expected 30-day readmissions for targeted conditions namely acute myocardial infraction, CHF, and pneumonia are penalized. A study of Medicare beneficiaries found that since the introduction of ACA and HRRP, there has been decrease in readmissions: 21.5% to 17.8% for targeted conditions and 15.3% to 13.1% for nontargeted conditions. 25 In future, ACA can include other chronic conditions including IBD, and hence it is important to look for modifiable factors to reduce readmissions.
Our study has several limitations. It is a retrospective study within a single health system, potentially limiting generalizability. As the University of Pennsylvania is a tertiary care medical center, the patients admitted to these hospitals may be sicker and may not be representative of all US hospitals and all clinical settings. Selection bias introduced by our specific patient population may explain our high readmission rates. We were also only able to assess those patients admitted and readmitted to our health system; therefore, we are unable to ascertain the impact of potential misclassification bias introduced by those having admissions at other medical centers and may have reported reduced readmission rates. This may have particularly impacted our assessment of those individuals who were uninsured. Our study did not evaluate postdischarge follow-up care of these patients. It is possible that medication changes or medical management decisions in the outpatient setting may also influence the subsequent risk of readmission. However, we chose to focus on short-term factors during the initial admission that may be modifiable and help reduce readmissions.
We suggest that future studies should focus on the strategies to reduce readmissions in patients with IBD. Studies on other chronic conditions such as CHF and COPD have noted that improved medication adherence and early postdischarge follow-up with specialists reduced readmission rates. 26, 27 In a large systematic review and meta-analysis, Rupper et al found that interventions to improve medication adherence among patients with CHF had significant effects on reducing readmissions (relative risk [RR] ¼ 0.89; 95% CI, 0.81-0.97) and decreased mortality (RR ¼ 0.89; 95% CI, 0.81-0.99). 26 A single-center retrospective study found that patients with COPD who did not attend their pulmonologist follow-up visit were at significant risk of rehospitalization within 90 days of discharge (OR ¼ 2.91; 95% CI, 1.06-8.01). 26 In summary, our study highlights that patients with IBD have a high rate of early and late readmissions. Although the most common indication for subsequent readmission was IBD, these patients were at particularly high risk of infection as well. Sicker patients with IBD (those admitted to ICU and who received TPN) are more likely to be readmitted, and special attention needs to be given to these patients at discharge to prevent readmissions. With increasing societal pressures to reduce expenditures in medical care, future prospective studies in larger cohorts of individuals are needed to identify modifiable risk factors to prevent readmissions and thereby reduce health care costs.
